Straits Times Index
3,212.64 -6.36 (-0.20%) Nikkei
27,385.25 -34.36 (-0.13%) Hang Seng
19,915.68 -133.96 (-0.67%) FTSE 100
7,389.11 -110.49 (-1.47%) Bitcoin USD
27,935.03 -720.00 (-2.51%) CMC Crypto 200
607.49 -10.90 (-1.76%)
VRTX Jan 2024 100.000 put
| Previous close | 1.2000 |
| Open | 1.2000 |
| Bid | 0.0000 |
| Ask | 2.4000 |
| Strike | 100.00 |
| Expiry date | 2024-01-19 |
| Day's range | 1.2000 - 1.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 28 |
- Zacks
Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool
This Cathie Wood Stock Could Nearly Double, According to Wall Street
One stock that could ride the market rally is CRISPR Therapeutics (NASDAQ: CRSP). This biotech is seeking to develop breakthrough therapies for difficult-to-treat illnesses using gene editing, and the company's focus in this area earned it a prominent place in the Ark Genomic Revolution ETF, an exchange-traded fund overseen by Cathie Wood. Wood isn't the only one on Wall Street who likes CRISPR.
- Motley Fool
This Is My Highest-Conviction Stock to Own in 2023 and Beyond
While one could say the same about many biotech companies, Vertex has an advantage very few of its peers do: For CF patients, it's the only game in town. Vertex markets the only medicines that target the underlying causes of CF. In 2022, the company's revenue of $8.93 billion jumped by 18% year over year.
